Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cord blood infusion now available for long COVID patients under expanded access

NCT ID NCT07332338

Disease control Sponsor: StemCyte, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program offers REGENECYTE, a human umbilical cord blood infusion, to adults with Long COVID who cannot join other clinical trials. Participants must have a recent negative COVID-19 test and provide consent. The goal is to provide potential treatment access while gathering safety data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human umbilical cord blood (REGENECYTE) infusion
What this could lead to
If it works, this could provide a treatment option for people with Long COVID who have no other trial options.
What could go wrong
This is an expanded access program, not a controlled trial, so results are uncertain. Risks of infusion include allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged ≥ 18 * With post-COVID condition * Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test) * Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE * Able to provide signed informed consent (by the subject or his/her legally authorized representative) * Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent Exclusion Criteria: * Neurological disorders prior to COVID-19 diagnosis * With pre-existing terminal illness * With known immune disease * Is pregnant or breastfeeding * Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening * Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period * Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases * Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic fatigue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic fatigue Chronic fatigue symptoms Fatigue post viral Long COVID Post COVID syndrome Post-COVID condition Post-COVID-19 condition

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • D&H National Research Center #1

    AVAILABLE

    Miami, Florida, 33169, United States

  • Myrak Research Center Inc.

    AVAILABLE

    Miami Lakes, Florida, 33014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.